China is increasingly becoming more than a global manufacturing base. As multinational companies expand research and development (R&D), advanced manufacturing, and innovation activities, the country is evolving into a strategic hub for global product development and technological innovation.
A growing number of international businesses are shifting from simply producing goods in China to building long-term innovation ecosystems that integrate local talent, supply chains, and research capabilities into their global operations.
French healthcare company Stago provides a clear example of this transformation. Its production facility in Tianjin—its first and only manufacturing base outside Europe—has evolved over the past two decades from a manufacturing site into an innovation center with local R&D capabilities.
By conducting research and product development in China, the company has significantly accelerated communication between its Chinese operations and headquarters, allowing faster decision-making, shorter development cycles, and quicker responses to customer needs.
The trend is reflected across multiple industries. During the first five months of 2026, nearly 4,000 foreign-invested enterprises expanded their investments in China, while multinational companies continued upgrading local operations from manufacturing facilities to innovation centers.
China’s expanding innovation ecosystem is attracting additional investment from global healthcare companies. Novo Nordisk recently announced an additional 200 million yuan investment in its Tianjin production base to increase manufacturing capacity, describing China as an increasingly important part of its global innovation strategy.
Similarly, GE HealthCare established its Magnetic Resonance Eastern Hemisphere Headquarters R&D Center in Tianjin, the company’s only system-level MRI research facility outside the United States. The center strengthens GE HealthCare’s global research network while supporting the development of next-generation medical imaging technologies.
Industry observers note that China’s strengths extend well beyond manufacturing. Its large talent pool, highly integrated industrial supply chains, fast commercialization capabilities, and supportive innovation policies enable multinational companies to accelerate product development and bring new technologies to market more efficiently.
Government policies are also encouraging continued investment. China’s 15th Five-Year Plan identifies biotechnology and healthcare as strategic emerging industries, creating additional opportunities for international companies to participate in China’s innovation-driven development.
Recent business surveys indicate that confidence among European companies operating in China is gradually recovering. Many multinational firms now see China not only as one of the world’s largest consumer markets but also as an essential location for research, product design, engineering, and technological collaboration.
As foreign companies continue expanding R&D investment and high-end manufacturing in China, the country is strengthening its position as a global innovation hub where international businesses can develop products for both the Chinese market and customers worldwide.
